BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36960055)

  • 1. Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment.
    Cruz Cruz J; Allison KC; Page LS; Jenkins AJ; Wang X; Earp HS; Frye SV; Graham DK; Verneris MR; Lee-Sherick AB
    Front Immunol; 2023; 14():1146721. PubMed ID: 36960055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting MerTK decreases efferocytosis and increases anti-tumor immune infiltrate in prostate cancer.
    Myers Chen KV; de Groot AE; Mendez SA; Mallin MM; Amend SR; Pienta KJ
    Med Oncol; 2023 Aug; 40(10):284. PubMed ID: 37644281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential polarization and the expression of efferocytosis receptor MerTK on M1 and M2 macrophages isolated from coronary artery disease patients.
    Mohd Idrus FN; Ahmad NS; Hoe CH; Azlan M; Norfuad FA; Yusof Z; Wan Isa WYH; Mohamed Ali AA; Yvonne-Tee GB
    BMC Immunol; 2021 Mar; 22(1):21. PubMed ID: 33761885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA-based modulation of macrophage-mediated efferocytosis potentiates antitumor immunity in colorectal cancer.
    Zhou X; Li D; Xia S; Ma X; Li R; Mu Y; Liu Z; Zhang L; Zhou Q; Zhuo W; Ding K; Lin A; Liu W; Liu X; Zhou T
    J Control Release; 2024 Feb; 366():128-141. PubMed ID: 38104775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression.
    Lin J; Xu A; Jin J; Zhang M; Lou J; Qian C; Zhu J; Wang Y; Yang Z; Li X; Yu W; Liu B; Tao H
    Oncoimmunology; 2022; 11(1):2024941. PubMed ID: 35036076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
    Lee-Sherick AB; Jacobsen KM; Henry CJ; Huey MG; Parker RE; Page LS; Hill AA; Wang X; Frye SV; Earp HS; Jordan CT; DeRyckere D; Graham DK
    JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptidoglycan from Bacillus anthracis Inhibits Human Macrophage Efferocytosis in Part by Reducing Cell Surface Expression of MERTK and TIM-3.
    Mytych JS; Pan Z; Lopez-Davis C; Redinger N; Lawrence C; Ziegler J; Popescu NI; James JA; Farris AD
    Immunohorizons; 2024 Mar; 8(3):269-280. PubMed ID: 38517345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.
    Myers KV; Amend SR; Pienta KJ
    Mol Cancer; 2019 May; 18(1):94. PubMed ID: 31088471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity.
    Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB
    Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MERTK tyrosine kinase receptor together with TIM4 phosphatidylserine receptor mediates distinct signal transduction pathways for efferocytosis and cell proliferation.
    Nishi C; Yanagihashi Y; Segawa K; Nagata S
    J Biol Chem; 2019 May; 294(18):7221-7230. PubMed ID: 30846565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efferocytosis is restricted by axon guidance molecule EphA4 via ERK/Stat6/MERTK signaling following brain injury.
    Soliman E; Leonard J; Basso EKG; Gershenson I; Ju J; Mills J; de Jager C; Kaloss AM; Elhassanny M; Pereira D; Chen M; Wang X; Theus MH
    J Neuroinflammation; 2023 Nov; 20(1):256. PubMed ID: 37941008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tim-3 facilitates immune escape in benzene-induced acute myeloid leukemia mouse model by promoting macrophage M2 polarization.
    Ning Q; Jian T; Cui S; Shi L; Jian X; He X; Zhang X; Li X
    Ecotoxicol Environ Saf; 2023 Nov; 266():115532. PubMed ID: 37806131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis.
    Chen R; Huang B; Lian M; Wei Y; Miao Q; Liang J; Ou Y; Liang X; Zhang H; Li Y; Xiao X; Wang Q; You Z; Chai J; Gershwin ME; Tang R; Ma X
    J Hepatol; 2023 Dec; 79(6):1478-1490. PubMed ID: 37659731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity.
    Nguyen KQ; Tsou WI; Calarese DA; Kimani SG; Singh S; Hsieh S; Liu Y; Lu B; Wu Y; Garforth SJ; Almo SC; Kotenko SV; Birge RB
    J Biol Chem; 2014 Sep; 289(37):25737-49. PubMed ID: 25074939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated expression of macrophage MERTK exhibits profibrotic effects and results in defective regulation of efferocytosis function in pulmonary fibrosis.
    She Y; Xu X; Yu Q; Yang X; He J; Tang XX
    Respir Res; 2023 Apr; 24(1):118. PubMed ID: 37120511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Cross-Linking of CD14 Activates MerTK and Promotes Human Macrophage Clearance of Apoptotic Neutrophils: the Dual Role of CD14 at the Crossroads Between M1 and M2c Polarization.
    Zizzo G; Cohen PL
    Inflammation; 2018 Dec; 41(6):2206-2221. PubMed ID: 30091033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L2
    Tavukcuoglu E; Horzum U; Yilmaz KB; Esendagli G
    Immunol Cell Biol; 2020 Feb; 98(2):152-164. PubMed ID: 31845380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mertk Interacts with Tim-4 to Enhance Tim-4-Mediated Efferocytosis.
    Moon B; Lee J; Lee SA; Min C; Moon H; Kim D; Yang S; Moon H; Jeon J; Joo YE; Park D
    Cells; 2020 Jul; 9(7):. PubMed ID: 32640697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BMS794833 inhibits macrophage efferocytosis by directly binding to MERTK and inhibiting its activity.
    Bae SH; Kim JH; Park TH; Lee K; Lee BI; Jang H
    Exp Mol Med; 2022 Sep; 54(9):1450-1460. PubMed ID: 36056187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mertk: An emerging target in cancer biology and immuno-oncology.
    Lahey KC; Gadiyar V; Hill A; Desind S; Wang Z; Davra V; Patel R; Zaman A; Calianese D; Birge RB
    Int Rev Cell Mol Biol; 2022; 368():35-59. PubMed ID: 35636929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.